Related Experiment Video
Updated: Oct 10, 2026
An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
Safety and immunogenicity of a paediatric presentation of an influenza vaccine
M Gonzalez1, M C Pirez, E Ward
1Centro Materno-Infantil Maciel, Montevideo, Uruguay.
Insights
This study shows that a new inactivated flu vaccine is safe and effective for children aged 6 months to 3 years. The prefilled syringe makes pediatric flu vaccination easier and helps prevent severe illness.
Area of Science:
- Pediatric Vaccinology
- Influenza Research
- Public Health
Background:
- Influenza vaccination is crucial for preventing severe illness in young children.
- Vaccination also aids in controlling influenza epidemic spread.
Purpose of the Study:
- To assess the safety and immunogenicity of a new pediatric influenza vaccine formulation.
- The vaccine is a purified, inactivated, triton split influenza vaccine.
Main Methods:
- 67 children under 3 years received two 0.25 ml doses of the vaccine, one month apart.
- The vaccine was administered using prefilled syringes.
Main Results:
- Most reactions to the pediatric flu vaccine were mild and temporary.
- Immunogenicity results exceeded European Community recommendations for adult doses.
Conclusions:
- The inactivated flu vaccine is safe and immunogenic in children aged 6 months to 3 years.
- The 0.25 ml prefilled syringe simplifies pediatric flu vaccine administration.
Background:
Flu vaccination in otherwise healthy infants and young children is important to prevent severe disease, as well as to control epidemic spread of influenza infection.
Aims:
To examine the safety and immunogenicity of a paediatric presentation of a purified, inactivated, triton split influenza vaccine.
Methods:
Two doses of the vaccine, provided in prefilled syringes of 0.25 ml, were administered, one month apart, to 67 children under 3 years of age.
Results:
Nine cases of immediate reaction to vaccination (macules/papules) were observed after the second injection only. During the study period, 9% of children experienced at least one delayed local reaction, and 28% of children presented at least one systemic reaction. Almost all reactions were mild and transient. Immunogenicity results surpassed the European Community recommendations for a 0.50 ml dose of vaccine in adults.
Conclusion:
This paediatric formulation of inactivated flu vaccine appears safe and immunogenic in children from 6 months to 3 years of age; the convenient presentation in a prefilled syringe of 0.25 ml volume will facilitate administration of the dose recommended for young children.
Related Concept Videos
01:51Vaccinations
01:29Respiratory Syncytial Virus Disease